Tocilizumab‐induced cytomegalovirus colitis in a patient with COVID‐19
journal contribution
submitted on 2023-03-15, 08:00 and posted on 2023-03-16, 06:18 authored by Mohamad Y. Khatib, Karimulla S. Shaik, Amna A. Ahmed, Mohammad A. Alwraidat, Ahmed S. Mohamed, Mohamad R. Abou Kamar, Mouhammad Z. Sharaf Eldean, Bashar K. Aldaraiseh, Abdulqadir J. Nashwan<p dir="ltr">The authors urge clinicians to observe for early signs of CMV reactivation in patients presenting with gastrointestinal bleeding and intestinal perforation after receiving tocilizumab or other immunosuppressive therapy as a treatment for COVID 19. Early recognition of CMV infection and treatment will prevent life-threatening bleeding and mortality.</p><h2>Other Information</h2><p dir="ltr">Published in: Clinical Case Reports<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="http://dx.doi.org/10.1002/ccr3.3487" target="_blank">http://dx.doi.org/10.1002/ccr3.3487</a></p>
Funding
Open Access funding provided by the Qatar National Library.
History
Related Materials
- 1.
- 2.
Language
- English
Publisher
WileyPublication Year
- 2020
License statement
This Item is licensed under the Creative Commons Attribution 4.0 International License.Institution affiliated with
- Hamad Medical Corporation
- Hazm Mebaireek General Hospital - HMC
